A successful Ph2 for myelofibrosis (SNT-5505) will see us taken out, most likely. This is the interim data being presented in December 2024 - 4 months away!
But if not a buyout, a licensing arrangement or partnership are most likely. A CR could be an option if we want to keep it all in-house and take the product to market ourselves, which is also a possibility, but a lot of money, time and effort to do so.
A successful Ph2 for myelofibrosis (SNT-5505) will see us taken...
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
-0.003(6.67%) |
Mkt cap ! $57.67M | |||
| Open | High | Low | Value | Volume |
| 4.4¢ | 4.5¢ | 4.2¢ | $37.11K | 834.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 244513 | 4.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 220000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| SNT (ASX) Chart |